I respect the opinion and commentary on GERN but I guess we'll have to agree to disagree on this one. The market didn't seem to have much concern with the announcement either as the stock actually closed up on Friday.
My investment rationale for GERN hinges not on GERN curing cancer or repairing spinal cord injuries in the next few years (or ever necessarily for that matter) but rather on the fact that you're dealing with what is arguably one of the leaders in embryonic stem cell research among the publicly traded biotechs. And I don't believe GERN needs to get any drugs on the market for this stock to go higher from current levels given their position as one of the dominant players in a promising field.
News 
Market Data 
Discover 
AI
